{
    "clinical_study": {
        "@rank": "161582", 
        "arm_group": [
            {
                "arm_group_label": "BVS857 Grp 1A open label", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "BVS857 Group 1B, 2, 3, 4 Double Blind", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo Group 1B, 2, 3, 4", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Study of tolerability and efficacy of BVS857 in severe burn subjects over 8 weeks and 15\n      weeks"
        }, 
        "brief_title": "Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects", 
        "completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypercatabolic Status Related to Severe Burn", 
        "condition_browse": {
            "mesh_term": "Burns"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Burn must be \u226520% total body surface area with expected need for surgical\n             intervention and not exceeding the sum of age plus burn size of 100 (Baux score)\n\n          -  Dosing must occur within 8-12 days post-burn\n\n          -  Subjects must weigh at least 45kgs (for group 1 with doses of 0.01mg/kg)  and be\n             under 100 kg to participate in the study\n\n        Exclusion Criteria:\n\n          -  Spinal cord injury\n\n          -  Hypoxic brain injury (Glasgow  Coma Scale  (GCS) <8) at screening\n\n          -  True conductive electric burn with suspected neurologic injury\n\n          -  Diabetics with HbA1c > 10%  or known history of hypoglycemia,\n\n          -  History of  or active peripheral neuropathy or seizure disorder\n\n          -  Systemic corticosteroids : > 10mg/d of prednisone or equivalent, use of anabolic\n             agents other than insulin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "48", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02074995", 
            "org_study_id": "CBVS857X2201"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "BVS857 Grp 1A open label", 
                    "BVS857 Group 1B, 2, 3, 4 Double Blind"
                ], 
                "description": "Group 1A&1B receive first dose as IV then remaining doses as SC. Goups 2, 3 and 4 receive only SC doses.", 
                "intervention_name": "BVS857", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Placebo Group 1B, 2, 3, 4", 
                "description": "Group 1B receive first dose as IV then remaining doses as SC. Goups 2, 3 and 4 receive only SC doses.", 
                "intervention_name": "placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Burn, Severe burn, Lean body mass, Cachexia, Hypermetabolism, Catabolism, Wound healing", 
        "lastchanged_date": "May 21, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Maywood", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60153"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Winston-Salem", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27157"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "43210"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75390"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Galveston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77555"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Multiple Ascending, Sequential, Placebo-controlled, Double-blind Study to Assess Safety, Tolerability and Efficacy of BVS857 in Severe Burn Subjects", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Number of patients with adverse events as a measure of safety and tolerability", 
                "measure": "Evaluate safety & tolerability of BVS857 in severe adult burn subjects", 
                "safety_issue": "Yes", 
                "time_frame": "Over 12 weeks"
            }, 
            {
                "description": "Total LBM is measured by dual energy X-ray absorptiometry (DXA) scan.", 
                "measure": "Efficacy measure by change in Lean Body Mass (LBM)", 
                "safety_issue": "No", 
                "time_frame": "Groups 2,3&4: Baseline, Day 35, Day 85 and Day 106"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02074995"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Serum Pharmacokinetics (PK) of BVS857: Cmax; The observed maximum plasma (or serum or blood) concentration following drug administration [mass / volume]", 
                "safety_issue": "No", 
                "time_frame": "Groups 1A&1B: Day 1through to Day 56: Groups 2,3&4:Day 1 through to Day 105"
            }, 
            {
                "measure": "Serum Pharmacokinetics (PK) of BVS857: Tmax; The time to reach the maximum concentration after drug administration [time]", 
                "safety_issue": "No", 
                "time_frame": "Groups 1A&1B: Day 1through to Day 56: Groups 2,3&4:Day 1 through to Day 105"
            }, 
            {
                "measure": "Serum Pharmacokinetics (PK) of BVS857: AUClast; The area under the plasma (or serum or blood) concentration-time curve from time zero to the time of the last quantifiable concentration [mass x time / volume]", 
                "safety_issue": "No", 
                "time_frame": "Groups 1A&1B: Day 1through to Day 56: Groups 2,3&4:Day 1 through to Day 105"
            }, 
            {
                "measure": "Serum Pharmacokinetics (PK) of BVS857: AUCinf; The area under the plasma (or serum or blood) concentration-time curve from time zero to infinity [mass x time / volume]", 
                "safety_issue": "No", 
                "time_frame": "Groups 1A&1B: Day 1through to Day 56: Groups 2,3&4:Day 1 through to Day 105"
            }, 
            {
                "measure": "Serum Pharmacokinetics (PK) of BVS857: T1/2; The terminal elimination half-life [time]", 
                "safety_issue": "No", 
                "time_frame": "Groups 1A&1B: Day 1through to Day 56: Groups 2,3&4:ay D1 through to Day 105"
            }, 
            {
                "measure": "Serum Pharmacokinetics (PK) of BVS857: CL; The systemic (or total body) clearance from plasma (or serum or blood) following intravenous administration [volume / time]", 
                "safety_issue": "No", 
                "time_frame": "Groups 1A&1B: Day 1through to Day 56: Groups 2,3&4:Day 1 through to Day 105"
            }, 
            {
                "measure": "Serum Pharmacokinetics (PK) of BVS857: Vz; The volume of distribution during the terminal elimination phase following intravenous administration [volume]", 
                "safety_issue": "No", 
                "time_frame": "Groups 1A&1B: Day 1through to Day 56: Groups 2,3&4:Day 1 through to Day 105"
            }, 
            {
                "measure": "Serum Pharmacokinetics (PK) of BVS857: Vss; The volume of distribution at steady state following intravenous administration [volume]", 
                "safety_issue": "No", 
                "time_frame": "Groups 1A&1B: Day 1through to Day 56: Groups 2,3&4:Day 1 through to Day 105"
            }, 
            {
                "measure": "Serum Pharmacokinetics (PK) of BVS857: Vz/F; The apparent volume of distribution during the terminal elimination phase following extravascular administration [volume]", 
                "safety_issue": "No", 
                "time_frame": "Groups 1A&1B: Day 1through to Day 56: Groups 2,3&4:Day 1 through to Day 105"
            }, 
            {
                "measure": "Serum Pharmacokinetics (PK) of BVS857: CL/F; The apparent systemic (or total body) clearance from plasma (or serum or blood) following extravascular administration [volume / time]", 
                "safety_issue": "No", 
                "time_frame": "Groups 1A&1B: Day 1through to Day 56: Groups 2,3&4:Day 1 through to Day 105"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}